November 24, 2016 - By Vivian Park · 0 Comments
The stock of ARNO THERAPEUTICS (OTCMKTS:ARNI) registered a decrease of 53.9% in short interest. ARNI’s total short interest was 6,500 shares in November as published by FINRA. Its down 53.9% from 14,100 shares, reported previously. With 5,100 shares average volume, it will take short sellers 1 days to cover their ARNI’s short positions. The stock closed at $0.3 during the last session. It is down 23.08% since April 22, 2016 and is downtrending. It has underperformed by 28.49% the S&P500.
Arno Therapeutics, Inc. is an early-stage firm focused on developing products for the treatment of cancer and other life threatening diseases. The company has a market cap of $13.46 million. The Company’s product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. It currently has negative earnings. Onapristone is indicated for endometrial, prostate and breast cancer indications.
Arno Therapeutics, Inc., incorporated on March 8, 2000, is an early-stage firm focused on developing products for the treatment of cancer and other life threatening diseases. The Company’s product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets.
More notable recent Arno Therapeutics Inc (OTCMKTS:ARNI) news were published by: Businesswire.com which released: “Arno Therapeutics Reports Third Quarter 2016 Financial and Business Update” on November 14, 2016, also Businesswire.com with their article: “Arno Therapeutics Reports Second Quarter 2016 Financial and Business Update” published on August 22, 2016, Seekingalpha.com published: “Past Failures Set Arno Therapeutics Up For Success.” on January 28, 2016. More interesting news about Arno Therapeutics Inc (OTCMKTS:ARNI) were released by: Globenewswire.com and their article: “Arno Therapeutics Completes $7.4 Million Common Stock Financing” published on January 13, 2016 as well as Globenewswire.com‘s news article titled: “Arno Therapeutics to Focus Clinical Developmental Activities on Advanced …” with publication date: April 19, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Vivian Park